Search Results for “Bayer” – Page 3 – media

Despite rough quarter, Bayer’s duo of Nubeqa and Kerendia continue to excel

As Bayer presented its first-quarter earnings, much of the focus centered on the company’s struggling agricultural sector, which has been hindered by the poor performance of its glyphosate-based weedkillers. Somewhat under the radar is Bayer’s pharma business, which could use a boost as well. On the company’s list of best-selling medicines, seven of the top 10 posted a sales decline from the first quarter of last year. That list doesn’t include the aging eye treatment Eylea, which was up 2% on the quarter. Still, the drug posted a sequential (PDF) sales decline of 4% from the fourth quarter of last year. It all adds up to lots of pressure to perform for Bayer’s most promising new treatments—prostate cancer drug Nubeqa and kidney disease therapy Kerendia. Bayer’s small dose of good news on Thursday is that both are progressing nicely. The company has projected the drugs will generate 3 billion euros ($3.2 billion) each at peak. During the ...
- Source: https://www.fiercepharma.com/pharma/rough-quarter-bayers-duo-nubeqa-kerendia-continue-excel
- 123
- May 14, 2023
Bayer’s Kerendia approved in the US to slow CKD in type 2 diabetes patients

Bayer’s first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) Kerendia has received approval in the US to slow chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D). The US Food and Drug Administration (FDA) has cleared Kerendia (finerenone) to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction (MI) and hospitalisation for heart failure in adult patients with CKD associated with T2D. The approval is based on data from the Phase III FIDELIO-DKD renal outcomes study, which showed Kerendia significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care. The drug also lowered the risk of a composite of time to first occurrence of CV death, non-fatal myocardial infarction, non-fatal stroke or heart failure hospitalisation, thereby by also meeting secondary targets. “Kerendia is the first and only nonsteroidal mineralocorticoid receptor ...
- Source: drugdu
- 1,036
- August 26, 2021
diabetes
Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion

By Ludwig Burger FRANKFURT (Reuters) – Bayer <BAYGn.DE> agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses. Germany’s Bayer will pay $2 billion upfront and up to an additional $2 billion in milestone payments contingent on development achievements, it said on Monday. The North Carolina-based takeover target, also known as AskBio, is trying to use the harmless adeno-associated virus as a delivery device to bring genetic repair kits against a range of diseases into the body.Drugs and farming pesticides maker Bayer needs to upgrade its drug development pipeline amid a weaker outlook for agricultural sales and as it seeks to finalise an $11 billion settlement over claims its Roundup weedkiller causes cancer. Among AskBio’s most advanced projects are early tests on volunteers of prospective treatments against Pompe disease – a ...
- Source: drugdu
- 283
- November 2, 2020
Gene therapy
Janssen, Bayer Plans to Shut South Korean Plants Seeing a Plunging Demand

Janssen Korea becomes yet another drugmaker to shut its Hyangnam plant in Hwaseong, South Korea, by 2021, stranding an uncounted number of employees.
- Source: FiercePharma
- 684
- August 8, 2018
Company Insight pharmaceutical company South Korea
Bayer to Sell its Brands to Denmark’s Leo Pharma

The German drugmaker Bayer has approved to sell its well-known prescription dermatology brands to Denmark’s Leo Pharma, as it focuses on integrating Monsanto also for strengthening its drug development pipeline.
- Source: Reuters
- 550
- August 2, 2018
Bayer Company Insight Dermatology
Bayer Sidelines Essure Concerns as Anecdotal, Legal Claims Build Up

A week post Bayer’s announcement on the withdrawal of Essure, its contraceptive implant from the market by this year-end due to inadequate sales, its clinical safety is questioned as consumer and legal stress builds up concerning complaints of extreme fatigue, pain and bleeding.
- Source: FierceBiotech
- 527
- July 30, 2018
Bayer Company Insight contraceptive device Essure
Bayer Announces the end of Essure Sales in the US

Bayer announced on last Friday that it would stop the sales of its Essure birth control system in the United States by the end of this year due to a steady decline in its sales making the product no longer justifiable. Bayer insisted that its decision to discontinue Essure sales is only for business reasons and not for any safety or efficacy concerns.
- Source: MDDI Online
- 644
- July 25, 2018
Company Insight contraceptive device FDA
FDA restricts sales of a Bayer’s Essure birth control device

The Food and Drug Administration(FDA) moved Monday to put sales restrictions on a Bayer birth control implant that has been a target of consumer criticism.
- Source: Usatoday
- 512
- April 11, 2018
Company Insights contraceptive device
Bayer announces completion of rolling submission of New Drug Application in the U.S. for larotrectinib for the treatment of TRK fusion cancer

Bayer today announced that its collaboration partner Loxo Oncology, Inc., (NASDAQ: LOXO), a biopharmaceutical company based in Stamford, Connecticut (US), has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
- Source: investor.bayer.de
- 593
- March 28, 2018
FDA larotrectinib New Approvals NTRK
Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancer (for specialized target groups only)

Bayer reported that the Chinese Food and Drug Administration (CFDA) approved Stivarga (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib) (Press release, Bayer, DEC 13, 2017, View Source [SID1234522618]).
- Source: 1stoncology
- 534
- March 20, 2018
HCC New Approvals Nexavar® Stivarga®

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.